Dr. Simpson explores the concept of remission in AD, focusing on minimal disease activity and long-term remission, discussing how disease modification in AD can impact the course of the disease and its associated comorbidities.
ERS 2024 | Understanding Remission as a Treatment Goal in Pediatric Severe Asthma – Patient Case Follow-Up
Pulmonology
In this ADVENT symposium at the 2024 European Respiratory Society conference, Dr. Leonard Bacharier revisits a patient case study where a biologic has been added to an asthma management plan and describes the potential for this patient to achieve on-therapy clinical remission.
IRS-ISIAN 2024 | Remission in CRSwNP: A Real-World Perspective
Rhinology
Prof. Eugenio De Corso describes the importance of real-world evidence for understanding the prospects of remission and the emerging evidence of biologic effectiveness for patients with CRSwNP.
ADVENT On Air | Charting a New Course: The Frontier of Early Intervention and Disease Modification in AD
Dermatology
Join Drs. April Armstrong and Lisa Beck for a conversation around the long-term burden and effects of AD. They will discuss the underlying pathophysiology of AD and how early intervention and disease modification may impact disease course.
ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.
For healthcare professionals in Algeria: Please read the additional Terms of Use.
Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.